What is OS Therapies's milestone payments?

OS Therapies (OSTX) reported milestone payments of $22.38M in Q1 2026.

How has OS Therapies's milestone payments changed year-over-year?

OS Therapies's milestone payments decreased by 0.0% year-over-year, from $22.38M to $22.38M.

What does milestone payments mean?

Payments made to third-party licensors or partners upon the achievement of specific clinical, regulatory, or commercial development goals. These payments are critical for assessing the capital intensity of the company's R&D pipeline.

OS Therapies OSTX Milestone Payments

Milestone Payments at other companies

InsmedINSM

$15M—

CTO

Citius Oncology, Inc.CTOR

$70M+155%

InsmedINSM

$15M—

Royalty PharmaRPRX

$50M0.0%

Climb Bio, Inc.CLYM

$8M—

HRO

HarrowHROW

$1.75M—

Other financials

Income statement

See full

Operating income-$10.2M-103%

Net income-$10.4M-168%

EPS (diluted)-$0.27-50.0%

Balance sheet

See full

Cash & equivalents$917.6K-69.1%

Total debt$20.0M—

Total equity-$10.8M-159%

Total assets$7.3M+71.7%

Cash flow

See full

Operating cash flow-$4.6M-32.6%

CapEx$316.4K—

Free cash flow-$3.7M—

Valuation

See full

Market cap$84.62M+65.5%

Enterprise value$103.7M—

Returns & leverage

See full

Return on equity470%—

Debt / equity-1.8×—

Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept osti:MilestonePayments.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's milestone payments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OS Therapies's milestone payments?: OS Therapies (OSTX) reported milestone payments of $22.38M in Q1 2026.
How has OS Therapies's milestone payments changed year-over-year?: OS Therapies's milestone payments decreased by 0.0% year-over-year, from $22.38M to $22.38M.
What does milestone payments mean?: Payments made to third-party licensors or partners upon the achievement of specific clinical, regulatory, or commercial development goals. These payments are critical for assessing the capital intensity of the company's R&D pipeline.